SignalHF vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (SignalHF) focuses on predicting heart failure hospitalizations within 30 days by analyzing data from cardiac implantable electronic devices. In contrast, Tool B (EchoGo Amyloidosis) is an AI-powered screening tool for the early detection of cardiac amyloidosis using echocardiogram video clips. While both are FDA-cleared cardiology AI solutions, they address distinct clinical problems and utilize different data sources, making them complementary rather than directly competitive.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
SignalHF by Implicity is an FDA-cleared AI algorithm designed to predict heart failure hospitalizations within 30 days. EchoGo Amyloidosis by Ultromics is an FDA-cleared AI-powered screening tool that aids in the early detection of cardiac amyloidosis from echocardiogram video clips.
SignalHF analyzes data from various cardiac implantable electronic devices (CIEDs), including physiological data, demographics, lead measurements, episodes, and therapies. EchoGo Amyloidosis analyzes echocardiogram video clips, focusing on echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement.
SignalHF generates automatic alerts for care teams based on heart failure risk scores, enabling early intervention and personalized care plans. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis.
SignalHF offers a unified platform for centralizing cardiac implantable device data. EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
SignalHF is intended for qualified healthcare professionals managing patients over 18 years old who are receiving physiological monitoring for heart failure surveillance and are implanted with compatible CIEDs. EchoGo Amyloidosis is indicated as a screening tool for adult patients aged 65 years and over with heart failure undergoing cardiovascular assessment using echocardiography.
The provided information for SignalHF does not specify accuracy metrics like sensitivity or specificity. EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity for detecting cardiac amyloidosis, with consistent performance across AL, wild-type ATTR, and variant ATTR subtypes.
SignalHF requires contacting the company for pricing details. EchoGo Amyloidosis provides specific pricing for inpatient analysis (NTAP Code ICD-10 XXE2X19 u2013 $1,000, Medicare-covered) and outpatient analysis (HCPCS Code C9786, Clinical APC Code 574 u2013 $285, covered by Medicare and select commercial insurers).